501 related articles for article (PubMed ID: 21378983)
1. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
[TBL] [Abstract][Full Text] [Related]
2. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
[TBL] [Abstract][Full Text] [Related]
4. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
5. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM
Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259
[TBL] [Abstract][Full Text] [Related]
6. Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Zhang J; Deng X; Choi HG; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Mar; 22(5):1864-9. PubMed ID: 22335897
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
9. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
[TBL] [Abstract][Full Text] [Related]
11. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
[TBL] [Abstract][Full Text] [Related]
12. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
[TBL] [Abstract][Full Text] [Related]
14. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP
Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237
[TBL] [Abstract][Full Text] [Related]
15. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
[TBL] [Abstract][Full Text] [Related]
16. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S; Liu M
Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
[TBL] [Abstract][Full Text] [Related]
17. Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.
Lee BD; Li X; Dawson TM; Dawson VL
Methods Mol Biol; 2012; 795():45-54. PubMed ID: 21960214
[TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
19. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
